Holen Sie sich die Stockscreener-App
14.16
1.80%
0.25
Janux Therapeutics Inc Aktie (JANX) Neueste Nachrichten
Pullback Watch: Will Janux Therapeutics Inc stock maintain dividend yieldJuly 2025 Weekly Recap & Daily Entry Point Trade Alerts - moha.gov.vn
Will Janux Therapeutics Inc. stock maintain dividend yield2025 Stock Rankings & Capital Efficiency Focused Ideas - ulpravda.ru
Aug Retail: Will Janux Therapeutics Inc. stock benefit from upcoming earnings reportsWeekly Trend Summary & Fast Exit Strategy with Risk Control - ulpravda.ru
Can Janux Therapeutics Inc. stock deliver sustainable ROEAnalyst Upgrade & Safe Swing Trade Setup Alerts - ulpravda.ru
Will Janux Therapeutics Inc. stock benefit from infrastructure spendingMarket Activity Recap & Weekly Setup with ROI Potential - ulpravda.ru
Why Janux Therapeutics Inc. stock remains resilientAutomated Trading Signals & Capital Planning and Optimization - ulpravda.ru
BofA Adjusts Price Target on Janux Therapeutics to $35 From $49, Maintains Buy Rating - MarketScreener
Janux Therapeutics (NASDAQ:JANX) Sets New 12-Month LowWhat's Next? - MarketBeat
Janux Therapeutics (NASDAQ:JANX) Nasdaq 100 Index Biotech Innovator - Kalkine Media
Janux Therapeutics initiated with a Peer Perform at Wolfe Research - MSN
Pre-market Movers: RSLS, STSS, VERO, KTTA... - RTTNews
Andrew Hollman Meyer Sells 1,879 Shares of Janux Therapeutics (NASDAQ:JANX) Stock - MarketBeat
Janux Therapeutics CEO Campbell sells $110k in stock By Investing.com - Investing.com Canada
Maria Dobek, Janux Therapeutics VP, sells $20k in shares By Investing.com - Investing.com Canada
Janux Therapeutics’ CMO McIver sells $37k in shares By Investing.com - Investing.com Nigeria
Janux Therapeutics CTO Winter sells $32,965 in shares By Investing.com - Investing.com Canada
Janux Therapeutics’ CMO McIver sells $37k in shares - Investing.com
Janux Therapeutics CBO Meyer sells $25,798 in stock By Investing.com - Investing.com Canada
Janux Therapeutics CSO sells $34k in shares By Investing.com - Investing.com Canada
Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 2,714 Shares of Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) CEO David Alan Campbell Sells 8,072 Shares of Stock - MarketBeat
Janux Therapeutics (NASDAQ:JANX) VP Maria Dobek Sells 1,462 Shares - MarketBeat
(JANX) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week LowHere's What Happened - MarketBeat
Is Janux Therapeutics Inc a good long term investmentEarnings Call Summaries & Exceptional Return Capital - earlytimes.in
Biotech Trio Gets Hammered On Heavy Trading - Finimize
Janux Therapeutics Earnings Notes - Trefis
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX) - Finviz
Why Wall Street sees big potential in Janux Therapeutics, Inc. (JANX) - MSN
TD Cowen Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Janux Therapeutics Inc (JANX) - The Globe and Mail
What analysts say about Janux Therapeutics Inc stockHead and Shoulders Patterns & High Yield Trading Signals - earlytimes.in
Janux Therapeutics Pipeline Remains on Track as JANX008 Advances, Wedbush Says - marketscreener.com
Janux Completes Phase 1a Dose-escalation In Phase 1 JANX008 Study; Expansion Cohorts To Commence - Nasdaq
Janux completes phase 1a dose-escalation for EGFR cancer drug By Investing.com - Investing.com UK
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study - New Castle News
Here are the most and least likely M&A targets in biotech, according to Truist - Seeking Alpha
How Janux Therapeutics Inc. (JANX) Affects Rotational Strategy Timing - Stock Traders Daily
Why Janux Therapeutics Inc. stock is favored by top institutions2025 Buyback Activity & Free Reliable Trade Execution Plans - Улправда
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Market Rankings: Is Janux Therapeutics Inc. stock supported by strong fundamentalsDay Trade & Verified High Yield Trade Plans - Улправда
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and Monte Rosa Therapeutics (GLUE) - The Globe and Mail
Big Money Moves: Is Janux Therapeutics Inc. stock supported by strong fundamentalsWeekly Profit Summary & Technical Buy Zone Confirmations - Улправда
Janux Therapeutics (NASDAQ:JANX) Sees Strong Trading VolumeShould You Buy? - MarketBeat
Why Janux Therapeutics Inc. stock remains a top recommendationMarket Rally & AI Driven Stock Movement Reports - Улправда
Is Janux Therapeutics Inc. stock a contrarian buyMarket Activity Summary & Daily Chart Pattern Signals - Улправда
Buyout Rumor: Why Janux Therapeutics Inc. stock is favored by top institutionsWeekly Profit Report & Capital Efficient Trade Techniques - Улправда
Barclays Sticks to Its Buy Rating for Janux Therapeutics Inc (JANX) - The Globe and Mail
Barclays Maintains Janux Therapeutics (JANX) Overweight Recommendation - Nasdaq
Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month LowHere's What Happened - MarketBeat
Squarepoint Ops LLC Raises Stock Position in Janux Therapeutics, Inc. $JANX - MarketBeat
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Barchart.com
0.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):